These two healthcare ETFs take fundamentally different approaches to investing, with meaningful differences in diversification, management strategy, and long-term return potential.
BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.
These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.
VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.
This is the newest page. Registered accounts read further back.